Polymorphic variations in the FANCA gene in high-risk non-BRCA1/2 breast cancer individuals from the French Canadian population

Molecular Oncology

Volumn 7, Issue 1, 2013, Pages 85-100

  Litim, Nadhir ^a   Labrie, Yvan ^a   Desjardins, Sylvie ^a   Ouellette, Geneviève ^a   Plourde, Karine ^a   Belleau, Pascal ^a   Durocher, Francine ^a  

^a UNIVERSITÉ LAVAL   (Canada)

Author keywords

Alternative splicing; Breast cancer susceptibility; FANCA variants; Fanconi anemia

Indexed keywords

AMINO ACID; BRAC2 PROTEIN; BRCA1 ASSOCIATED RING DOMAIN PROTEIN 1; CYSTEINE; FANCONI ANEMIA GROUP A PROTEIN; MEMBRANE PROTEIN; METHIONINE; PHENYLALANINE; RNA; SERINE; THREONINE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BREAST CANCER; CANADA; CELL IMMORTALIZATION; CODING; COMPUTER MODEL; COMPUTER PROGRAM; CONTROLLED STUDY; DNA PURIFICATION; FRANCE; GENE AMPLIFICATION; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; HIGH RISK PATIENT; HUMAN; INTRON; MAJOR CLINICAL STUDY; MISSENSE MUTATION; MUTATIONAL ANALYSIS; POLYMORPHIC VARIANT; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION; RNA SPLICING; SEQUENCE ANALYSIS;

EID: 84872490795     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2012.08.002     Document Type: Article

References (68)

1. Akbari R., Malekzadeh R., Lepage P., Roquis D., Sadjadi A., Aghcheli K., Yazdanbod A., Shakeri R., Bashiri J., Sotoudeh M., Pourshams A., Ghadirian P., Narod S. Mutations in Fanconi anemia genes and the risk of esophageal cancer. Hum. Genet. 2011, 129:573-582.
2. Antoniou A.C., Durocher F., Smith P., Simard J., Easton D.F. INHERIT BRCAs program members. BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families. Breast Cancer Res. 2006, 8(1):R3. Epub 2005 Dec 12.
3. Berwick M., Satagopan J.M., Ben-Porat L., Carlson A., Mah K., Henry R., Diotti R., Milton K., Pujara K., Landers T., Dev Batish S., Morales J., Schindler D., Hanenberg H., Hromas R., Levran O., Auerbach A.D. Genetic heterogeneity among Fanconi anemia heterozygotes and risk of cancer. Cancer Res. 2007, 67:9591-9596.
4. Bond G.L., Hu W., Bond E.E., Robins H., Lutzker S.G., Arva N.C., Bargonetti J., Bartel F., Taubert H., Wuerl P., Onel K., Yip L., Hwang S.J., Strong L.C., Lozano G., Levine A.J. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 2004, 119:591-602.
5. Bouchlaka C., Abdelhak S., Amouri A., Ben Abid H., Hadiji S., Frikha M., Ben Othman T., Amri F., Ayadi H., Hachicha M., Rebaï A., Saad A., Dellagi K., Tunisian Fanconi Anemia Study Group Fanconi anemia in Tunisia: high prevalence of group A and identification of new FANCA mutations. J. Hum. Genet. 2003, 48:352-361.
6. Callén E., Tischkowitz M.D., Creus A., Marcos R., Bueren J.A., Casado J.A., Mathew C.G., Surrallés J. Quantitative PCR analysis reveals a high incidence of large intragenic deletions in the FANCA gene in Spanish Fanconi anemia patients. Cytogenet. Genome Res. 2004, 104:341-345.
7. Cantor S.B., Bell D.W., Ganesan S., Kass E.M., Drapkin R., Grossman S., Wahrer D.C., Sgroi D.C., Lane W.S., Haber D.A., Livingston D.M. BACH1, a novel helicase-like protein, interacts directly with BRCA1 and contributes to its DNA repair function. Cell 2001, 105:149-160.
8. Cantor S., Drapkin R., Zhang F., Lin Y., Han J., Pamidi S., Livingston D.M. The BRCA1-associated protein BACH1 is a DNA helicase targeted by clinically relevant inactivating mutations. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:2357-2362.
9. Cartegni L., Wang J., Zhu Z., Zhang M.Q., Krainer A.R. ESEfinder: a web resource to identify exonic splicing enhancers. Nucleic Acids Res. 2003, 31:3568-3571.
10. Castella M., Pujol R., Callén E., Trujillo J.P., Casado J.A., Gille H., Lach F.P., Auerbach A.D., Schindler D., Benítez J., Porto B., Ferro T., Muñoz A., Sevilla J., Madero L., Cela E., Beléndez C., de Heredia C.D., Olivé T., de Toledo J.S., Badell I., Torrent M., Estella J., Dasí A., Rodríguez-Villa A., Gómez P., Barbot J., Tapia M., Molinés A., Figuera A., Bueren J.A., Surrallés J. Origin, functional role, and clinical impact of Fanconi anemia FANCA mutations. Blood 2011, 117:3759-3769.
11. Centra M., Memeo E., d'Apolito M., Savino M., Ianzano L., Notarangelo A., Liu J., Doggett N.A., Zelante L., Savoia A. Fine exon-intron structure of the Fanconi anemia group A (FAA) gene and characterization of two genomic deletions. Genomics 1998, 51:463-467.
12. De Winter J.P., van der Weel L., de Groot J., Stone S., Waisfisz Q., Arwert F., Scheper R.J., Kruyt F.A., Hoatlin M.E., Joenje H. The Fanconi anemia protein FANCF forms a nuclear complex with FANCA, FANCC and FANCG. Hum. Mol. Genet. 2000, 9:2665-2674.
13. Desjardins S., Beauparlant C.J., Labrie Y., Ouellette G., Simard J., BRCAs I.N.H.E.R.I.T., Durocher F. Variations in the Nijmegen Breakage Syndrome gene, NBN/NBS1, and the risk of breast cancer in high-risk non-BRCA1 and BRCA2 French Canadian breast cancer ovarian cancer families. BMC Cancer 2009, 9:181.
14. Desjardins S., Belleau P., Labrie Y., Ouellette G., Bessette P., Chiquette J., Laframboise R., Lépine J., Lespérance B., Pichette R., Plante M., BRCAs I.N.H.E.R.I.T., Durocher F. Genetic variants and haplotype analyses of the ZBRK1/ZNF350 gene in high-risk non BRCA1/2 French Canadian breast and ovarian cancer families. Int. J. Cancer 2008, 122:108-116.
15. Desmet F.O., Hamroun D., Lalande M., Collod-Béroud G., Claustres M., Béroud C. Human Splicing Finder: an online bioinformatics tool to predict splicing signals. Nucleic Acids Res. 2009, 37:e67.
16. Dietz H.C., Valle D., Francomano C.A., Kendzior R.J., Pyeritz R.E., Cutting G.R. The skipping of constitutive exons in vivo induced by nonsense mutations. Science 1993, 259:680-683.
17. Durocher F., Labrie Y., Soucy P., Sinilnikova O., Labuda D., Bessette P., Chiquette J., Laframboise R., Lépine J., Lespérance B., Ouellette G., Pichette R., Plante M., Tavtigian S.V., Simard J. Mutation analysis and characterization of ATR sequence variants in breast cancer cases from high-risk French Canadian breast/ovarian cancer families. BMC Cancer 2006, 6:230.
18. Erkko H., Xia B., Nikkila J., Schleutker J., Syrjakoski K., Mannermaa A., Kallioniemi A., Pylkas K., Karppinen S.M., Rapakko K., Miron A., Sheng Q., Li G., Mattila H., Bell D.W., Haber D.A., Grip M., Reiman M., Jukkola-Vuorinen A., Mustonen A., Kere J., Aaltonen L.A., Kosma V.M., Kataja V., Soini Y., Drapkin R.I., Livingston D.M., Winqvist R. A recurrent mutation in PALB2 in Finnish cancer families. Nature 2007, 446:316-319.
19. Ferrer M., Rodríguez J.A., Spierings E.A., de Winter J.P., Giaccone G., Kruyt F.A. Identification of multiple nuclear export sequences in Fanconi anemia group A protein that contribute to CRM1-dependent nuclear export. Hum. Mol. Genet. 2005, 14:1271-1281.
20. Folias A., Matkovic M., Bruun D., Reid S., Hejna J., Grompe M., D'Andrea A., Moses R. BRCA1 interacts directly with the Fanconi anemia protein FANCA. Hum. Mol. Genet. 2002, 11:2591-2597.
21. Hasselbach L., Haase S., Fischer D., Kolberg H.C., Stürzbecher H.W. Characterisation of the promoter region of the human DNA-repair gene Rad51. Eur. J. Gynaecol. Oncol. 2005, 26:589-598.
22. Knipscheer P., Räschle M., Smogorzewska A., Enoiu M., Ho T.V., Schärer O.D., Elledge S.J., Walter J.C. The Fanconi anemia pathway promotes replication-dependent DNA interstrand cross-link repair. Science 2009, 326:1698-1701.
23. Kozak M. Point mutations define a sequence flanking the AUG initiator codon that modulates translation by eukaryotic ribosomes. Cell 1986, 44:283-292.
24. Lensch M.W., Tischkowitz M., Christianson T.A., Reifsteck C.A., Speckhart S.A., Jakobs P.M., O'Dwyer M.E., Olson S.B., Le Beau M.M., Hodgson S.V., Mathew C.G., Larson R.A., Bagby G.C. Acquired FANCA dysfunction and cytogenetic instability in adult acute myelogenous leukemia. Blood 2003, 102:7-16.
25. Levran O., Diotti R., Pujara K., Batish S.D., Hanenberg H., Auerbach A.D. Spectrum of sequence variations in the FANCA gene: an International Fanconi anemia Registry (IFAR) study. Hum. Mutat. 2005, 25:142-149.
26. Levran O., Doggett N.A., Auerbach A.D. Identification of Alu-mediated deletions in the Fanconi anemia gene FAA. Hum. Mutat. 1998, 12:145-152.
27. Mathe E., Olivier M., Kato S., Ishioka C., Hainaut P., Tavtigian S.V. Computational approaches for predicting the biological effect of p53 missense mutations: a comparison of three sequence analysis based methods. Nucleic Acids Res. 2006, 34:1317-1325.
28. Mathew C.G. Fanconi anemia genes and susceptibility to cancer. Oncogene 2006, 25:5875-5884.
29. Medhurst A.L., Huber P.A., Waisfisz Q., de Winter J.P., Mathew C.G. Direct interactions of the five known Fanconi anemia proteins suggest a common functional pathway. Hum. Mol. Genet. 2001, 10:423-429.
30. Medhurst A.L., Laghmani el H., Steltenpool J., Ferrer M., Fontaine C., de Groot J., Rooimans M.A., Scheper R.J., Meetei A.R., Wang W., Joenje H., de Winter J.P. Evidence for subcomplexes in the Fanconi anemia pathway. Blood 2006, 108:2072-2080.
31. Meindl A., Hellebrand H., Wiek C., Erven V., Wappenschmidt B., Niederacher D., Freund M., Lichtner P., Hartmann L., Schaal H., Ramser J., Honisch E., Kubisch C., Wichmann H.E., Kast K., Deissler H., Engel C., Müller-Myhsok B., Neveling K., Kiechle M., Mathew C.G., Schindler D., Schmutzler R.K., Hanenberg H. Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene. Nat. Genet. 2010, 42:410-414.
32. Moldovan G.L., D'Andrea A.D. How the fanconi anemia pathway guards the genome. Annu. Rev. Genet. 2009, 43:223-249.
33. Morgan N.V., Tipping A.J., Joenje H., Mathew C.G. High frequency of large intragenic deletions in the Fanconi anemia group A gene. Am. J. Hum. Genet. 1999, 65:1330-1341.
34. Najafi M., Jangravi Z. Human PON promoters: from similarity to prediction of polymorphic positions within transcription factor elements. Mini Rev. Med. Chem. 2010, 10:938-945.
35. Nakamura A., Matsuura S., Tauchi H., Hanada R., Ohashi H., Hasagawa T., Honda K., Masuno M., Imaizumi K., Sugita K., Ide T., Komatsu K. Four novel mutations of the Fanconi anemia group A gene (FAA) in Japanese patients. J. Hum. Genet. 1999, 44:48-51.
36. Naylor J.A., Green P.M., Rizza C.R., Giannelli F. Analysis of factor VIII mRNA reveals defects in everyone of 28 haemophilia A patients. Hum. Mol. Genet. 1993, 2:11-17.
37. Ng P.C., Henikoff S. SIFT: predicting amino acid changes that affect protein function. Nucleic Acids Res. 2003, 31:3812-3814.
38. Notredame C., Higgins D.G., Heringa J. T-Coffee: a novel method for fast and accurate multiple sequence alignment. J. Mol. Biol. 2000, 302:205-217.
39. Otsuki T., Furukawa Y., Ikeda K., Endo H., Yamashita T., Shinohara A., Iwamatsu A., Ozawa K., Liu J.M. Fanconi anemia protein, FANCA, associates with BRG1, a component of the human SWI/SNF complex. Hum. Mol. Genet. 2001, 10:2651-2660.
40. Pang Z., Yao L., Zhang J., Ouyang T., Li J., Wang T., Fan Z., Fan T., Lin B., Xie Y. RAD51C germline mutations in Chinese women with familial breast cancer. Breast Cancer Res. Treat. 2011 May 20, (Epub ahead of print).
41. Rahman N., Seal S., Thompson D., Kelly P., Renwick A., Elliott A., Reid S., Spanova K., Barfoot R., Chagtai T., Jayatilake H., McGuffog L., Hanks S., Evans D.G., Eccles D., Easton D.F., Stratton M.R. PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat. Genet. 2007, 39:165-167. Breast Cancer Susceptibility Collaboration (UK).
42. Ramensky V., Bork P., Sunyaev S. Human non-synonymous SNPs: server and survey. Nucleic Acids Res. 2002, 30:3894-3900.
43. Raschle M., Knipscheer P., Enoiu M., Angelov T., Sun J., Griffith J.D., Ellenberger T.E., Schärer O.D., Walter J.C. Cell 2008, 134:969-980.
44. Reese M.G., Eeckman F.H., Kulp D., Haussler D. Improved splice site detection in genie. J. Comput. Biol. 1997, 4:311-323.
45. Reuter T., Herterich S., Bernhard O., Hoehn H., Gross H.J. Strong FANCA/FANCG but weak FANCA/FANCC interaction in the yeast 2-hybrid system. Blood 2000, 95:719-720.
46. Ricketts M.H., Simons M.J., Parma J., Mercken L., Dong Q., Vassart G. A nonsense mutation causes hereditary goitre in the Afrikander cattle and unmasks alternative splicing of thyroglobulin transcripts. Proc. Natl. Acad. Sci. U. S. A. 1987, 84:3181-3184.
47. Savino M., Borriello A., D'Apolito M., Criscuolo M., Del Vecchio M., Bianco A.M., Di Perna M., Calzone R., Nobili B., Zatterale A., Zelante L., Joenje H., Della Ragione F., Savoia A. Spectrum of FANCA mutations in Italian Fanconi anemia patients: identification of six novel alleles and phenotypic characterization of the S858R variant. Hum. Mutat. 2003, 22:338-339.
48. Seal S., Barfoot R., Jayatilake H., Smith P., Renwick A., Bascombe L., McGuffog L., Evans D.G., Eccles D., Easton D.F., Stratton M.R., Rahman N. Breast cancer susceptibility Collaboration. Evaluation of Fanconi anemia genes in familial breast cancer predisposition. Cancer Res. 2003, 63:8596-8599.
49. Seal S., Thompson D., Renwick A., Elliott A., Kelly P., Barfoot R., Chagtai T., Jayatilake H., Ahmed M., Spanova K., North B., McGuffog L., Evans D.G., Eccles D., Easton D.F., Stratton M.R., Rahman N. Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. Nat. Genet. 2006, 38:1239-1241. Breast Cancer Susceptibility Collaboration (UK).
50. Simard J., Dumont M., Moisan A.M., Gaborieau V., Malouin H., Durocher F., Chiquette J., Plante M., Avard D., Bessette P., Brousseau C., Dorval M., Godard B., Houde L., BRCAs I.N.H.E.R.I.T., Joly Y., Lajoie M.A., Leblanc G., Lépine J., Lespérance B., Vézina H., Parboosingh J., Pichette R., Provencher L., Rhéaume J., Sinnett D., Samson C., Simard J.C., Tranchant M., Voyer P., Easton D., Tavtigian S.V., Knoppers B.M., Laframboise R., Bridge P., Goldgar D. Evaluation of BRCA1 and BRCA2 mutation prevalence, risk prediction models and a multistep testing approach in French-Canadian families with high risk of breast and ovarian cancer. J. Med. Genet. 2007, 44:107-121.
51. Smith P.J., Zhang C., Wang J., Chew S.L., Zhang M.Q., Krainer A.R. An increased specificity score matrix for the prediction of SF2/ASF-specific exonic splicing enhancers. Hum. Mol. Genet. 2006, 15:2490-2508.
52. Solyom S., Winqvist R., Nikkilä J., Rapakko K., Hirvikoski P., Kokkonen H., Pylkäs K. Screening for large genomic rearrangements in the FANCA gene reveals extensive deletion in a Finnish breast cancer family. Cancer Lett. 2011, 302:113-118.
53. Somyajit K., Subramanya S., Nagaraju G. RAD51C: a novel cancer susceptibility gene is linked to Fanconi anemia and breast cancer. Carcinogenesis 2010, 31:2031-2038.
54. Sridharan D., Brown M., Lambert W.C., McMahon L.W., Lambert M.W. Nonerythroid alphaII spectrin is required for recruitment of FANCA and XPF to nuclear foci induced by DNA interstrand cross-links. J. Cell. Sci. 2003, 116:823-835.
55. Stratton M.R., Rahman N. The emerging landscape of breast cancer susceptibility. Nat. Genet. 2008, 40:17-22.
56. Sunyaev S., Ramensky V., Koch I., Lathe W., Kondrashov A.S., Bork P. Prediction of deleterious human alleles. Hum. Mol. Genet. 2001, 10:591-597.
57. Tachibana A., Kato T., Ejima Y., Yamada T., Shimizu T., Yang L., Tsunematsu Y., Sasaki M.S. The FANCA gene in Japanese Fanconi anemia: reports of eight novel mutations and analysis of sequence variability. Hum. Mutat. 1999, 13:237-244.
58. Tamary H., Bar-Yam R., Shalmon L., Rachavi G., Krostichevsky M., Elhasid R., Barak Y., Kapelushnik J., Yaniv I., Auerbach A.D., Zaizov R. Fanconi anaemia group A (FANCA) mutations in Israeli non-Ashkenazi Jewish patients. Br. J. Haematol. 2000, 111:338-343.
59. Tavtigian S.V., Deffenbaugh A.M., Yin L., Judkins T., Scholl T., Samollow P.B., de Silva D., Zharkikh A., Thomas A. Comprehensive statistical study of 452 BRCA1 missense substitutions with classification of eight recurrent substitutions as neutral. J. Med. Genet. 2006, 43:295-305.
60. Thompson E., Dragovic R.L., Stephenson S.A., Eccles D.M., Campbell I.G., Dobrovic A. A novel duplication polymorphism in the FANCA promoter and its association with breast and ovarian cancer. BMC Cancer 2005, 5:43.
61. Tipping A.J., Pearson T., Morgan N.V., Gibson R.A., Kuyt L.P., Havenga C., Gluckman E., Joenje H., de Ravel T., Jansen S., Mathew C.G. Molecular and genealogical evidence for a founder effect in Fanconi anemia families of the Afrikaner population of South Africa. Proc. Natl. Acad. Sci. U. S. A 2001, 98:5734-5739.
62. Tischkowitz M., Easton D.F., Ball J., Hodgson S.V., Mathew C.G. Cancer incidence in relatives of British Fanconi anaemia patients. BMC Cancer 2008, 8:257.
63. Wang W. Emergence of a DNA-damage response network consisting of Fanconi anaemia and BRCA proteins. Nat. Rev. Genet. 2007, 8:735-748.
64. Wang S.S., Bratti M.C., Rodríguez A.C., Herrero R., Burk R.D., Porras C., González P., Sherman M.E., Wacholder S., Lan Z.E., Schiffman M., Chanock S.J., Hildesheim A. Common variants in immune and DNA repair genes and risk for human papillomavirus persistence and progression to cervical cancer. J. Infect. Dis. 2009, 199:20-30.
65. Wijker M., Morgan N.V., Herterich S., van Berkel C.G., Tipping A.J., Gross H.J., Gille J.J., Pals G., Savino M., Altay C., Mohan S., Kokal I., Cavenagh J., Marsh J., van Weel M., Ortega J.J., Schuler D., Samochatova E., Karwacki M., Bekassy A.N., Abecasis M., Ebell W., Kwee M.L., de Ravel T., Mathew C.G. Heterogeneous spectrum of mutations in the Fanconi anemia group A gene. Eur. J. Hum. Genet. 1999, 7:52-59.
66. Yagasaki H., Hamanoue S., Oda T., Nakahata T., Asano S., Yamashita T. Identification and characterization of novel mutations of the major Fanconi anemia gene FANCA in the Japanese population. Hum. Mutat. 2004, 24:481-490.
67. Zheng Y., Zhang J., Hope K., Niu Q., Huo D., Olopade O.I. Screening RAD51C nucleotide alterations in patients with a family history of breast and ovarian cancer. Breast Cancer Res. Treat. 2010, 124:857-861.
68. Zhu Y., Spitz M.R., Lei L., Mills G.B., Wu X. A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter enhances lung cancer susceptibility. Cancer Res. 2001, 61:7825-7829.